Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
3–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Consent of parent or legal guardian required
Chronic HCV infection genotype 2 or 3
Screening laboratory values within defined thresholds
PK Lead-in only: all individuals must be treatment naive
You may not be if
History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus
Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)
Pregnant or nursing females
Known hypersensitivity to study medication
Use of any prohibited concomitant medications as within 28 days of the Day 1 visit
Clareo Health | Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
